INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Clinical trial NCT06295731 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06295731
Sponsor: Inhibrx Biosciences, Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC)

Start date: 2024-05-14
Primary completion: 2029-05-01
Enrollment: 410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.